Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market

 
• By Joseph Haas

Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.

Diabetes
Lilly's initial Phase III data for its dual GIP/GLP-1 agonist look competitive

More from Clinical Trials

More from R&D